

## Original Article

# Correlation Between Endoscopic and Histological Findings of Dyspeptic Patients and their Association with *Helicobacter Pylori* Infection

Saifa Kismat<sup>1</sup>, Nusrat Noor Tanni<sup>1</sup>, Rokshana Akhtar<sup>1</sup>, Chandan Kumar Roy<sup>1</sup>, Mohammad Mosiur Rahman<sup>2</sup>  
Shaheda Anwar<sup>1</sup>, Sharmeen Ahmed<sup>1</sup>

<sup>1</sup>Department of Microbiology and Immunology Bangabandhu Sheikh Mujib Medical University

<sup>2</sup>Department of Pathology, Bangabandhu Sheikh Mujib Medical University

### Abstract

There is a high prevalence of *H. pylori* infection in Bangladeshi population that causes site specific diseases which includes gastritis, gastric ulcer, duodenal ulcer and gastric carcinoma. The Cross sectional study was carried out in the Department of Microbiology and immunology, Bangabandhu Medical University (BSMMU), during the period of September, 2018 to July, 2019. Dyspeptic patients, who underwent endoscopic examination at the Department of Gastroenterology of Dhaka medical College and Hospital, who fulfilled the inclusion criteria were enrolled as study population. Collected gastric and duodenal biopsy specimens from 142 patients were categorized as *H. pylori* positive cases (34.5%) and *H. pylori* negative cases (35.2%) based on the case definition used in the study by RUT, Histology and *ureC* gene PCR. All of the laboratory works were performed at Department of Microbiology and Immunology except Histology which was performed at the Department of Pathology of BSMMU. Endoscopic findings significantly co-related with histological findings ( $p = 0.001$ ). Highest rate of *H. pylori* infection was found in 76% of duodenal ulcer cases and lowest in Adenocarcinoma group being only 9% of total study population. *H. pylori* infection was positively associated with duodenal ulcer cases ( $p=0.014$ ) and negatively with adeno carcinoma cases ( $p=0.002$ ) in a statistically significant manner.

**Key words:** *H. pylori*, Gastroduodenal disease, Dyspepsia

### Introduction

There is a high prevalence (67%) of *H. pylori* infection in Bangladeshi population.<sup>1</sup> Commonest symptom of *H. pylori* infection, dyspepsia is considered as one of the most common causes of patient's referrals to Gastroenterology Centers.<sup>2</sup> Dyspepsia is generally defined as chronic or frequently recurring epigastric pain or discomfort originating in gastro duodenal region and may be accompanied with other gastrointestinal symptoms such as nausea, belching, vomiting, postprandial fullness and early satiety.<sup>3</sup> In Asia 8%-30% people suffer from dyspepsia.<sup>4</sup> Prevalence of *H. pylori* infection in dyspeptic patient in India was 32.9% among the adult population.<sup>5</sup> Overcrowding, bad sanitation and unhealthy practice favor high prevalence of *H.pylori* in Bangladesh.<sup>6,7</sup> The best specimens for isolation of *H. pylori* are biopsy samples

obtained during endoscopy.<sup>8</sup> The association of *H. pylori* with gastritis, duodenal ulcer and gastric cancer has been reported by investigators from different countries all over the world including ours.<sup>9,10,11,12,13</sup>

### Materials and Methods

The Cross sectional study was carried out in the Department of Microbiology and immunology, Bangabandhu Medical University (BSMMU), during the period of September, 2018 to July, 2019.

### Patient selection and Sample Collection

Dyspeptic patients, who underwent endoscopic examination at the Department of Gastroenterology of Dhaka Medical College and Hospital, aged from 18 to onward presenting with symptoms of dyspepsia for more than one month were included in the study.<sup>14</sup> Patients who received *H. pylori* eradication treatment in the previous 2 months<sup>15</sup>, elderly individuals (65 years), had severe medical or surgical illnesses or used proton pump inhibitors, nonsteroidal anti-inflammatory drugs, colloidal bismuth compounds, or antibiotics within 4 weeks of enrollment

---

Correspondence:

**Dr. Saifa Kismat**

Department of Microbiology and Immunology  
Bangabandhu Sheikh Mujib Medical University, Dhaka.  
Phone : 01731992307, E-mail: shifasaifakismat@gmail.com

were excluded from the study.<sup>16</sup> Collected gastric and duodenal biopsy specimens from 142 patients were categorized as *H. pylori* positive cases (34.5%) and *H. pylori* negative cases (35.2%). According to case definition used in this study, patients were considered as *H. pylori* positive when positive results were obtained in at least two of the three tested methods Rapid urease test (RUT), histology for *H. pylori* and PCR for *ureC* gene and considered as negative when the results of all diagnostic tests were negative. Patients positive by only one test were considered as indeterminate or doubtful case. Gastroduodenal diseases were diagnosed by endoscopic and histopathological examination and established in accordance with the Sydney System Classification.

### Laboratory Procedures

All of the laboratory works were performed at Department of Microbiology and Immunology except Histology which was performed at the department of Pathology of BSMMU.

Total four to five pieces of gastric tissue specimens were taken from gastric antrum, body and margins of the lesion. One specimen collected from the antrum was immediately placed into a screw capped bottle containing rapid urease test media to detect the presence of *H. pylori*. Two specimens were collected from the antrum and body, preserved in 1.5 ml micro centrifuge tube containing 1 ml phosphate buffer solution for detection of *H. pylori ureC* gene and stored at -20°C until DNA extraction from the samples were performed. One to two specimens, each collected from margins of erosion, ulcer or growth were collected in a screw capped plastic pot containing 10% buffered formalin and was sent to the Department of Pathology, BSMMU for histological examination.

### Histological Examination

Tissue sections were prepared and stained with Hematoxylin and Eosin (H&E) for the diagnosis of gastroduodenal diseases and modified Giemsa stain for *H. pylori* detection. The biopsy specimens were analyzed by a pathologist without knowledge of the clinical and endoscopic finding of the patients.


### Category of study population on the basis of Histological findings

The study population were diagnosed as chronic gastritis, chronic gastric ulcer, duodenal ulcer, intestinal metaplasia and gastric carcinoma by histological examination. For evaluation of results of the study, gastroduodenal diseases were categorized into three groups- a) Gastritis, b) Peptic ulcer diseases (chronic gastric ulcer and duodenal

ulcer) and c) Gastric carcinoma and/or precancerous lesions (intestinal metaplasia and gastric adenocarcinoma group).<sup>17,18</sup>

### DNA Extraction and ureC Gene PCR

DNA from gastric tissues were extracted by using the QIAamp (QIAGEN) DNA Mini Kit according to the manufacturer's instructions. For confirming the presence of *H. pylori* DNA in tissue, the *ureC* gene was identified by PCR using the following forward and reverse primer- A A G C T T T T A G G G G T G T T A G G G - G T T T ; A A G C T - T A C T T T C T A A C A C T A A C G C.<sup>19</sup> The DNA were denatured at 94°C for 5 minutes, followed by 35 cycles at 93°C for 1 minute, 55°C for 30 seconds, and 72°C for 1 minute with a final extension at 72°C for 10 minutes. The PCR product was analyzed in 2% agarose gel with ethidium bromide which was prepared in 1xTAE (Tris Acetic acid EDTA- Ethylene diamine tetra acetic acid) buffer by electrophoresis for 30 minutes to detect specific band of 294 bp.



**Figure-I:** Agarose gel electrophoresis analysis showed amplified DNA product of *ureC* (294 bp). Lane P =positive results. Positive control (PC): *ureC* positive *H. pylori*, negative control (NC): amplified product of PCR without DNA.

### Statistical Analysis

The prevalence of *H. pylori* infection by PCR for *ureC* gene and rapid urease test, from gastric mucosal biopsy is 67%<sup>1</sup> in Bangladeshi population. Acceptable error was 5%. The statistical analysis was performed using SPSS software package version-23 (IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp). The Chi-square test or Fisher's exact test were used to compare between proportions. Values of  $p < 0.05$  were considered statistically significant.

## Results




Figure-II: shows the Bar diagram of sex distribution among endoscopic findings of study population.

Table-I: Endoscopic findings of the study population in relation to age (n=142).

Age group (in year)	Endoscopic findings				
	Normal n (%)	Gastritis n (%)	Gastric ulcer n (%)	Ulcero-proliferative growth n (%)	Duodenal ulcer n (%)
18-25 (15)	1(16.6)	7(9.4)	1(3.5)	1(7.1)	5(25)
26-35 (21)	1(16.6)	13(17.5)	3(10.7)	0(0)	4(20)
36-45 (32)	1(16.6)	18(24.3)	8(28.5)	1(7.1)	4(20)
46-55 (34)	3(50)	16(21.6)	7(25)	4(28.5)	4(20)
56-65 (27)	0 (0)	14(18.9)	6(21.4)	4(28.5)	3(15)
66-75 (10)	0(0)	4(5.4)	2(7.1)	4(28.5)	0(0)
>75 (3)	0(0)	2(2.7)	1(3.5)	0(0)	0(0)
<b>Total (142)</b>	<b>6(100)</b>	<b>74(100)</b>	<b>28(100)</b>	<b>14(100)</b>	<b>20(100)</b>

Table I shows among 142 total cases, majority (74) were endoscopically reported as gastritis, followed by gastric ulcer (28), duodenal ulcer (20), ulcero-proliferative growth (14) and normal cases (6). The study population ranged from 18 to more than 75 years of age, with mean age  $46.2 \pm 15.9$  years. Majority of gastritis (24.3%) and gastric ulcer (28.5%) patients were in age group 36-45 years of age. Most cases of ulcero-proliferative growth were observed at a frequency of 4 (28.5%) in every decade starting from 46 years to 75 years. Most of the duodenal ulcer cases 5 (25%) were found between 18-55 years of age.

Table-II: Relation between Endoscopic findings and histological findings of study population

Endoscopic findings	Histological Findings						p value
	Gastritis n (%)	Chronic gastric ulcer n (%)	Duodenal ulcer n (%)	Intestinal metaplasia n (%)	Adeno carcinoma n (%)	Not enough tissue n (%)	
Normal (n=6)	6(100)	0(0)	0(0)	0(0)	0(0)	0(0)	
Gastritis (n=74)	70(94.5)	0(0)	0(0)	3(4.0)	0(0)	1(1.3)	
Gastric ulcer(n=28)	15(53.5)	10(35.7)	0(0)	2(7.1)	1(3.5)	0(0)	
Ulcero-proliferative growth (n=14)	2(14.2)	0(0)	0(0)	0(0)	12(85.7)	0(0)	0.001*
Duodenal ulcer (n=20)	0(0)	0(0)	20(100)	0(0)	0(0)	0(0)	
<b>Total =142</b>	<b>93</b>	<b>10</b>	<b>20</b>	<b>5</b>	<b>13</b>	<b>1</b>	

s = significant

The relation between endoscopic and histological findings are shown in Table-II.

All endoscopically diagnosed normal cases (6) were diagnosed as gastritis of various grades. Among 74 endo-scopically reported gastritis cases 70 (94.5) had gastritis, 3 (4%) had intestinal metaplasia and 1 (1.3) specimen did not contain enough tissue for histological diagnosis in histology. Out of 28 endoscopically diagnosed gastric ulcer cases; 15 (53.5) were diagnosed as gastritis, 10 (35.7) as chronic gastric ulcer, 2 (7.1%) as intestinal metaplasia and 1 (3.5%) as adenocarcinoma in histology. All (20) of the duodenal ulcer cases in endoscopy were diagnosed as duodenal ulcer in histology. Out of 14 ulcero-proliferative growth in endoscopy 12(85.7%) were diagnosed as adenocarcinoma and 2(14.2) as gastritis in histology. Endoscopic findings were significantly co-related with histological findings (p = 0.001).

Table-III: Detection of *H. pylori* by three invasive diagnostic tests; (n=142)

Name of the test	Number of Positive (%)
<b>Rapid urease test</b>	<b>86 (60.6)</b>
<b>Histological staining</b>	<b>35 (24.6)</b>
<b>PCR for ureC gene</b>	<b>41 (28.9)</b>

Table-III shows detection rate of *H. pylori* by three invasive diagnostic tests.

**Table-IV: Category of study population as per case definition (n=142):**

Study population	Number of cases (%)
<i>H. pylori</i> positive cases	49 (34.5%)
<i>H. pylori</i> negative cases	50 (35.2)
<i>H. pylori</i> indeterminate cases	43(30%)

Table IV shows, Out of 142 cases 49 (34.5%) cases were defined as *H. pylori* positive cases, 50 (35.2) were defined as *H. pylori* negative cases. 43 (30.2) cases were considered as doubtful or indeterminate cases as they yielded only one test positive.

**Table-V: Distribution of gastro-duodenal diseases among *H. pylori* positive and negative cases**

Group	Gastroduodenal disease	Case definition		p value
		<i>H. pylori</i> positive cases	<i>H. pylori</i> negative cases	
Gastritis group (59)	Gastritis (n=59)	30(50.8)	29(49.1)	0.743 <sup>ns</sup>
PUD group (25)	Chronic gastric ulcer (n=8)	3(37.5)	5(62.5)	0.479 <sup>ns</sup>
	Duodenal ulcer (n=17)	13(76.4)	4(23.5)	0.014 <sup>s</sup>
Carcinoma & precancerous group (15)	Adeno-carcinoma (n=12)	1(9.0)	11(91.6)	0.002 <sup>s</sup>
	Metaplasia (n=3)	2(66.6)	1(33.3)	0.545 <sup>ns</sup>

s = significant

ns = not significant

Table V shows-Highest rate of *H. pylori* infection in 76% (13/17) of duodenal ulcer cases and lowest rate of infection found in Adenocarcinoma 9% (1/12) cases. *H. pylori* infection was positively associated with duodenal ulcer cases (p=0.014) and negatively with adeno carcinoma cases (p=0.002) in a statistically significant manner.

## Discussion

Demographic data obtained in this study correlated with the findings of a previously conducted similar study in Dhaka, Bangladesh.<sup>20</sup> Most of the study population, 91(64%) were male and only 51, (36%) were female, male female ratio being 1.7:1 in both studies. Male predominance of *H. pylori* infection in adult is a global and homogeneous phenomenon.<sup>21,22,23</sup> This can be

explained by differences in the exposure to environmental factors such as higher prevalence of smoking in men<sup>24</sup>, Sex hormones affecting immunity and the inflammatory response to *H. pylori* differently in men and women.<sup>25,26</sup> The study population ranged from 18 to more than 75 years of age, with mean age being  $46.2 \pm 15.9$  years. Most cases of ulcero-proliferative growth were observed after the age of 45 years. The finding reflects the fact that gastric cancer is rare before the age of 40, but its incidence steadily climbs thereafter.<sup>27</sup> Among 142 total cases, majority were endoscopically reported as gastritis patients followed by 28% gastric ulcer, 20% duodenal ulcer and 14% ulcero-proliferative growth which is similar to another study conducted in Dhaka.<sup>12</sup> All endoscopically diagnosed normal cases (6) were diagnosed as gastritis of various grades. Among 74 endoscopically reported gastritis cases 70 (94.5%) had gastritis of various grades, 3 (4%) had intestinal metaplasia. Endoscopic gastritis has a good correlation with histologic gastritis however normal endoscopic appearance is a poor predictor of histologic gastritis.<sup>28</sup> It is also in line with the findings that normal gastric mucosa could be correctly diagnosed endoscopically in about 80% of cases.<sup>29</sup> Most 15 (53.5%) of the endoscopically diagnosed gastric ulcer cases; were diagnosed as gastritis, 10 (35.7%) as chronic gastric ulcer, 2 (7.1%) as intestinal metaplasia and 1 (3.5%) as adenocarcinoma in histology. Similar to another study where 50% of endoscopically diagnosed gastric ulcer cases were diagnosed as gastritis and adenocarcinoma of stomach in histopathology.<sup>11</sup> Out of 14 ulcero-proliferative growth in endoscopy 12 (85.7%) were diagnosed as adenocarcinoma and 2 (14.2) as gastritis in histology. Similar correlations were found in another study of Bangladesh.<sup>11</sup>

In this study detection of *H. pylori* was done by three invasive diagnostic tests; rapid urease test, histological staining (Modified Giemsa) and PCR amplifying *ureC* gene. RUT was positive in 86 (60.6%) cases. In other studies of Bangladesh, where rapid urease could detect *H. pylori* in 54.05%<sup>1</sup> and 53.3%<sup>30</sup> cases. In our study *H. pylori* was detected in 35 (24.6%) cases by modified Giemsa staining. Similar to 25.71%<sup>11</sup> and 34.4%<sup>30</sup> from gastric biopsy specimens. In contrast with 73.68%<sup>31</sup> *H. pylori* positive by histological staining. Sensitivity and reliability of histology increases with the number and localization of the collected biopsy specimens. It is ideal to obtain two biopsy specimens from the antrum and two from the corpus.<sup>8</sup> Obtaining only one sample for histology might have decreased the positivity of histological examination in this study. *ureC* gene was detected by PCR in 41 (28.9%) cases in this present study. Similar finding 31%<sup>32</sup> *H. pylori* positive cases in gastric biopsy by *ureC* gene PCR.

According to case definition used in this study, out of 142 cases 49 (34.5%) cases were defined as *H. pylori* positive cases as they were *H. pylori* positive by at least two of the three tests and 50 (35.2%) were defined as *H. pylori* negative cases as they were *H. pylori* negative by all three tests. Rest of the 43 (30%) cases were positive only by rapid urease test. This is similar to the finding of Iranian (31%)<sup>33</sup> and Bangladeshi (47%)<sup>6</sup> study. Higher *H. pylori* prevalence rates were described to be 60.2%<sup>30</sup> to 76.7%<sup>34</sup> by both invasive and noninvasive methods in other studies. Prevalence of *H. pylori* infection varies between and within geographic regions depending on socioeconomic factors. Its prevalence also varies depending on the method used to detect infection because gastric biopsy-based tests may give false negative results due to sampling error and serological tests may provide false positive results as they cannot differentiate current infection from past exposure.<sup>35</sup> In this study, only 1-2 gastric biopsy tissue was used in each test for determining *H. pylori*, while the organism is unevenly distributed throughout the gastric mucosa; this could also be a contributing factor to the lower prevalence of the present study. Moreover, the noncompliance of the participant with not using proton pump inhibitor four weeks prior to endoscopic examination might produce a false negative result with RUT, culture and histology. Unjudicial use of antibiotics for other diseases may contribute in false negative results. Recently, several studies from Asian and Middle East countries reported declining trend in *H. pylori* infection with improvement of hygienic condition.<sup>36,37,38</sup>

In the study, highest infection rate of *H. pylori* 76.4% was observed in duodenal ulcer cases and lowest being only one (9.1%) in adeno carcinoma cases. In contrast to the findings of 100% of duodenal ulcer and 60% gastritis patients having *H. pylori* infection<sup>1</sup> in another study. In this study 66.6% of intestinal metaplasia had *H. pylori* infection. *H. pylori* acts as a promoter in the progression from normal to metaplastic epithelium, possibly by inducing a hyper proliferative state in the inflamed gastric mucosa.<sup>39</sup> Regarding low prevalence of *H. pylori* in only one (9.0%) of carcinoma cases of our study, it is close to another study where 27.5% of *H. pylori* was found in adeno carcinoma cases.<sup>11</sup> In gastric cancer patients, glandular atrophy and intestinal metaplasia, which are considered to be the precursor of gastric cancer, are frequently found in the biopsy specimen. Glandular atrophy and intestinal metaplasia prevent adequate evaluation of *H. pylori* status in patients with gastric cancer, as these are the environments in which *H. pylori* might disappear. Moreover, the distribution of atrophy and intestinal metaplasia is uneven, and that

might also affect the sensitivity of the various biopsy sites.<sup>40</sup>

### Conclusion

Endoscopic examination can be used as a good method for diagnosis of gastric diseases in absence of histopathology as significant co-relation with histological findings was observed. However normal endoscopic appearance is a poor predictor of histologic gastritis. *H. pylori* infection maybe positively associated with duodenal ulcer cases and negatively with adeno carcinoma cases in a statistically significant manner. The sample size of the included studies were relatively small especially for individual disease analysis. The study was conducted in a single hospital in Dhaka, Bangladesh; therefore, the participants may not have been representative of the Bangladeshi population as a whole.

**Acknowledgments:** This study was funded by Bangladesh Medical Research Council.

### References

1. Habib AM, Alam J, Rudra B, Quader A and Al-Forkan M. Analysis of *Helicobacter pylori* prevalence in Chittagong, Bangladesh, based on PCR and CLO test. *Microbiology insights* 2016;9:39858.
2. Mapel D, Roberts M, Overhiser A, Mason A. The epidemiology, diagnosis, and cost of dyspepsia and *Helicobacter pylori* gastritis: a case-control analysis in the Southwestern United States. *Helicobacter* 2013;18(1):54-65.
3. Ramin N, Mehrdad S, Mohammad RF, Amirreza D, Laleh M. Prevalence of *Helicobacter pylori* in patients with dyspepsia. *Jundishapur J Microbiol* 2014; 7(9):12676
4. Ghoshal UC, Singh R, Chang FY, Hou X, Wong BCY, and Kachintorn U. Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. *Journal of neurogastroenterology and motility* 2011;17(3):235.
5. Srinivas Y, Prasad PK, and Sai ND. Prevalence and impact of *Helicobacter pylori* in dyspepsia. *International Surgery Journal* 2016;3(1):305-309.
6. Aftab H, Yamaoka Y, Ahmed F, et al. Validation of diagnostic tests and epidemiology of *Helicobacter pylori* infection in Bangladesh. *The Journal of Infection in Developing Countries* 2018;12(05): 305-12.
7. Ahmad MM, Rahman M, Rumi AK, et al. Prevalence of *Helicobacter pylori* in asymptomatic population a pilot serological study in Bangladesh. *Journal of Epidemiology* 1997;7: 251-54

8. Mègraud F, Lehours P. *Helicobacter pylori* detection and antimicrobial susceptibility testing. Clin. Microbiol. Rev 2007;20(2):280-322.
9. Dooley CP. Background and historical considerations of *Helicobacter pylori*. Gastroenterology Clinics of North America 1993;22: 2-4.
10. Blaser MJ. *Helicobacter pylori* and the pathogenesis of gastroduodenal inflammation. Journal of Infectious diseases 1990;161: 626-633.
11. Sultana A, Badruddoza SM and Rahman F. Correlation between endoscopic and histological findings in different gastro-duodenal lesion and its association with *Helicobacter pylori*. Anwer Khan Modern Medical College Journal 2011;2(2):6-10.
12. Saha R, Ahmed S, Sattar H, et al. Association of *H. pylori cagA* Gene with Duodenal Ulcer & Gastric Carcinoma in Bangladeshi Patients. American Journal of Microbiological Research 2018; 6(2):57-62.
13. Vakil N, Rhew D, Soll A, and Ofman JJ, The Cost Effectiveness of Diagnostic Testing Strategies for *Helicobacter pylori*. The American Journal of Gastroenterology 2000;95: 1692-1698.
14. Islam MDU, Rahman SHZ, Shamsuzzaman SM, et al. Comments on Evaluation of Endoscopic Findings and Detection of *H. pylori* Antibody by Serum IgG ELISA. Faridpur Medical College Journal 2011; 6 (1): 24-7.
15. Tongtawee T, Dechsukhum C, Leeanansaksiri W, et al. Improved detection of *Helicobacter pylori* infection and premalignant gastric mucosa using "site specific biopsy": a randomized control clinical trial. Asian Pacific Journal of Cancer Prevention 2015;16(18): 8487-90
16. Ye BD, Kim SG, Park JH, Kim JS, Jung HC and Song IS. The interleukin-8-251 A allele is associated with increased risk of noncardia gastric adenocarcinoma in *Helicobacter pylori*-infected Koreans. Journal of clinical gastroenterology 2009;43(3): 233-39.
17. Ramis IB, Vianna JS, Gonzalves CV, Von Groll A, Dellagostin OA and da Silva PEA et al. Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected with *Helicobacter pylori*. Journal of Microbiology, Immunology and Infection 2017;50(2):153-59.
18. Marshall B and Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet 1984;323(8390): 1311-15.
19. Lu JJ, Perng CL, Shyu RY, Chen CH, Lou Q, Chong SK. Comparison of Five PCR Methods for Detection of *Helicobacter pylori* DNA in Gastric Tissues. Journal of clinical microbiology 1999; 37(3): 772-74.
20. Saha R, Ahmed S, Sattar H. Association of *H. pylori cagA* Gene with Duodenal Ulcer & Gastric Carcinoma in Bangladeshi Patients. American Journal of Microbiological Research 2018; 6(2):57-62.
21. De Martel C and Parsonnet J. *Helicobacter pylori* infection and gender: a meta-analysis of population-based prevalence surveys. Digestive diseases and sciences 2006;51(12): 2292-2301.
22. Naja F, Kreiger N, and Sullivan T. *Helicobacter pylori* infection in Ontario: prevalence and risk factors. Canadian Journal of Gastroenterology and Hepatology 2007;21(8):501-506.
23. Ibrahim A, Morais S, Ferro A, Lunet N and Peleteiro B. Sex-differences in the prevalence of *Helicobacter pylori* infection in pediatric and adult populations: systematic review and meta-analysis of 244 studies. Digestive and Liver Disease 2017; 49(7):742-49.
24. Marakoglu K, Eke AA, Civi S. Smoking as an important factor increasing risk of *Helicobacter pylori*. Turkish Journal of Gastroenterology 2008;19:133-4.
25. Sipponen P, Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer 2002; 5: 213-19.
26. Verthelyi D. Sex hormones as immunomodulators in health and disease. International Immunopharmacology 2001;1: 983-93
27. Gore RM. Gastric cancer Clinical and pathologic features. Radiologic clinics of North America 1997; 35(2):295-310.
28. Jemilohun AC, Otegbayo JA, Ola SO, Oluwasola AO and Akere A. Correlation between Endoscopic and Histological Gastritis in South-Western Nigerians with Dyspepsia. Nigerian Journal of Gastroenterology and Hepatology 2010;2(2):73-6.
29. Levy N, Stermer E and Boss JM. Accuracy of endoscopy in the diagnosis of inflamed gastric and duodenal mucosa. Israel journal of medical sciences 1985;21(7):564-68

30. Rahman SH, Rahman MA, Arfin MS, et al. *Helicobacter pylori* Infection and Strain Types in Adult Dyspeptic Patients Undergoing Endoscopy in a Specialized Hospital of Dhaka City. *Bangladesh Journal of Medical Microbiology* 2009;3(1):4-9.
31. Wani FA, Bashir G, Khan MA, Zargar SA, Rasool Z, and Qadri Q. Antibiotic Resistance in *Helicobacter pylori*: A Mutational Analysis from a Tertiary Care Hospital in Kashmir, India. *Indian Journal of Medical Microbiology* 2018;36(2):266.
32. Pandya HB, Agravat HH, and Patel JS. Prevalence of Specific *Helicobacter Pylori* *cagA*, *vacA*, *iceA*, *ureC* Genotypes and its Clinical Relevance in the Patients with Acid-Peptic Diseases. *Journal of clinical and diagnostic research: JCDR* 2017;11(8):DC23.
33. Niknam R, Seddigh M, Fattahi MR, Dehghanian A, and Mahmoudi L. Prevalence of *Helicobacter pylori* in patients with dyspepsia. *Jundishapur journal of microbiology* 2014;7(10).
34. Matsuhisa T, Aftab H. Observation of gastric mucosa in Bangladesh, the country with the lowest incidence of gastric cancer and Japan, the country with the highest incidence. *Helicobacter* 2012;17: 396-401.
35. Vaira D & Vakil N. Blood, urine, stool, breath, money and *Helicobacter pylori*. *Gut* 2001;48: 287e289.
36. Chen J, Bu XL, Wang QY, Hu PJ and Chen MH. Decreasing seroprevalence of *Helicobacter pylori* infection during 1993-2003 in Guangzhou, southern China. *Helicobacter* 2007;12(2):164-169.
37. Alazmi WM, Siddique I, Alateeqi N, Al-Nakib B. Prevalence of *Helicobacter pylori* infection among new outpatients with dyspepsia in Kuwait. *BMC Gastroenterol* 2010;10: 14.
38. Yim JY, Kim N, Choi SH, et al. Seroprevalence of *Helicobacter pylori* in South Korea. *Helicobacter* 2007;12: 333-340.
39. Scott N, Lansdown M, Diament R. Helicobacter gastritis and intestinal metaplasia in a gastric cancer family. *Lancet* 1990;335: 728
40. Kim CG, Choi IJ, Lee JY, et al. Biopsy site for detecting *Helicobacter pylori* infection in patients with gastric cancer. *Journal of gastroenterology and hepatology* 2009;24(3):469-74.